Correction to: AI (Re)Defining Pharmaceutical Exclusivities, by Jonathan Kimball and Srividhya Ragavan, Biotechnol Law Rep 2022;41(1):23–29; doi: 10.1089/blr.2021.29257.sr

Abstract

Biotechnology Law ReportVol. 41, No. 2 CorrectionOpen AccessCorrection to: AI (Re)Defining Pharmaceutical Exclusivities, by Jonathan Kimball and Srividhya Ragavan, Biotechnol Law Rep 2022;41(1):23–29; doi: 10.1089/blr.2021.29257.sris erratum ofAI (Re)Defining Pharmaceutical ExclusivitiesPublished Online:12 Apr 2022https://doi.org/10.1089/blr.2021.29257.sr.correxAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail In the February 2022 issue of Biotechnology Law Report (vol. 41, no. 1; 23–29), the article titled AI (Re)Defining Pharmaceutical Exclusivities, by Jonathan Kimball and Srividhya Ragavan requires correction.In the original article, the author's affiliation statement for Jonathan Kimball appeared as: “Jonathan Kimball is the Vice President for Trade and International Affairs at the Association for Accessible Medicines in Washington, DC, USA. Srividhya Ragavan is a Professor of Law and Faculty Director of the India Program at Texas A&M School of Law in Fort Worth, Texas, USA. A version of this argument was presented at the University of the Pacific Law School and a part of that published with Sofia Vegas as Reconsidering the Rationale for the Duration of Data Exclusivity, 51U. Pac. L. Rev. 525 (2020). E-mail for Prof. Ragavan: ragavan.sri@law.tamu.edu.”It should have appeared as: “Jonathan Kimball has worked for 15 years on pharmaceutical policy issues impacting both the brand and generic industries. Srividhya Ragavan is a Professor of Law and Faculty Director of the India Program at Texas A&M School of Law in Fort Worth, Texas, USA. A version of this argument was presented at the University of the Pacific Law School and a part of that published with Sofia Vegas as Reconsidering the Rationale for the Duration of Data Exclusivity, 51U. Pac. L. Rev. 525 (2020). E-mail for Prof. Ragavan: ragavan.sri@law.tamu.edu. The views expressed in this article are those of the authors and do not necessarily represent the organizations for which they work.”The online version has been corrected to reflect this.FiguresReferencesRelatedDetailsRelated articlesAI (Re)Defining Pharmaceutical Exclusivities11 Feb 2022Biotechnology Law Report Volume 41Issue 2Apr 2022 InformationCopyright 2022, Mary Ann Liebert, Inc., publishersTo cite this article:Correction to: AI (Re)Defining Pharmaceutical Exclusivities, by Jonathan Kimball and Srividhya Ragavan, Biotechnol Law Rep 2022;41(1):23–29; doi: 10.1089/blr.2021.29257.sr.Biotechnology Law Report.Apr 2022.118-118.http://doi.org/10.1089/blr.2021.29257.sr.correxcreative commons licensePublished in Volume: 41 Issue 2: April 12, 2022Online Ahead of Print:April 4, 2022PDF download